Literature DB >> 10543949

Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes.

L Chen1, T J Rydel, F Gu, C M Dunaway, S Pikul, K M Dunham, B L Barnett.   

Abstract

Matrix metalloproteinases are believed to play an important role in pathological conditions such as osteoarthritis, rheumatoid arthritis and tumor invasion. Stromelysin is a zinc-dependent proteinase and a member of the matrix metalloproteinase family. We have solved the crystal structure of an active uninhibited form of truncated stromelysin and a complex with a hydroxamate-based inhibitor. The catalytic domain of the enzyme of residues 83-255 is an active fragment. Two crystallographically independent molecules, A and B, associate as a dimer in the crystals. There are three alpha-helices and one twisted, five-strand beta-sheet in each molecule, as well as one catalytic Zn, one structural Zn and three structural Ca ions. The active site of stromelysin is located in a large, hydrophobic cleft. In particular, the S1' specificity site is a deep and highly hydrophobic cavity. The structure of a hydroxamate-phosphinamide-type inhibitor-bound stromelysin complex, formed by diffusion soaking, has been solved as part of our structure-based design strategy. The most important feature we observed is an inhibitor-induced conformational change in the S1' cavity which is triggered by Tyr223. In the uninhibited enzyme structure, Tyr223 completely covers the S1' cavity, while in the complex, the P1' group of the inhibitor displaces the Tyr223 in order to fit into the S1' cavity. Furthermore, the displacement of Tyr223 induces a major conformational change of the entire loop from residue 222 to residue 231. This finding provides direct evidence that Tyr223 plays the role of gatekeeper of the S1' cavity. Another important intermolecular interaction occurs at the active sit of molecule A, in which the C-terminal tail (residues 251-255) from molecule B inserts. The C-terminal tail interacts extensively with the active site of molecule A, and the last residue (Thr255) coordinated to the catalytic zinc as the fourth ligand, much like a product inhibitor would. The inhibitor-induced conformational change and the intermolecular C-terminal-zinc coordination are significant in understanding the structure-activity relationships of the enzyme. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543949     DOI: 10.1006/jmbi.1999.3147

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  13 in total

1.  Apparent tradeoff of higher activity in MMP-12 for enhanced stability and flexibility in MMP-3.

Authors:  Xiangyang Liang; A Arunima; Yingchu Zhao; Rajagopalan Bhaskaran; Anuradha Shende; Todd S Byrne; Jeremy Fleeks; Mark O Palmier; Steven R Van Doren
Journal:  Biophys J       Date:  2010-07-07       Impact factor: 4.033

2.  Calcium regulates tertiary structure and enzymatic activity of human endometase/matrilysin-2 and its role in promoting human breast cancer cell invasion.

Authors:  Seakwoo Lee; Hyun I Park; Qing-Xiang Amy Sang
Journal:  Biochem J       Date:  2007-04-01       Impact factor: 3.857

3.  Entropy increases from different sources support the high-affinity binding of the N-terminal inhibitory domains of tissue inhibitors of metalloproteinases to the catalytic domains of matrix metalloproteinases-1 and -3.

Authors:  Ying Wu; Shuo Wei; Steven R Van Doren; Keith Brew
Journal:  J Biol Chem       Date:  2011-03-28       Impact factor: 5.157

4.  A multidisciplinary approach to probing enthalpy-entropy compensation and the interfacial mobility model.

Authors:  Erin M Wilfong; Yuri Kogiso; Sivaramakrishnan Muthukrishnan; Thomas Kowatz; Yu Du; Amber Bowie; James H Naismith; Christopher M Hadad; Eric J Toone; Terry L Gustafson
Journal:  J Am Chem Soc       Date:  2011-07-07       Impact factor: 15.419

5.  Matrix metalloproteinase (MMP)-3 polymorphism in patients with HBV related chronic liver disease.

Authors:  Hyun Phil Shin; Joung Il Lee; Joo-Ho Jung; Sung-Vin Yim; Hyun Jeong Kim; Jae Myung Cha; Jong Beom Park; Kwang Ro Joo; Jae Seok Hwang; Byoung-Kuk Jang
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

6.  Matrix metalloproteinase-inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitors.

Authors:  Luis A Alcaraz; Lucia Banci; Ivano Bertini; Francesca Cantini; Antonio Donaire; Leonardo Gonnelli
Journal:  J Biol Inorg Chem       Date:  2007-08-21       Impact factor: 3.358

7.  Solution structure of inhibitor-free human metalloelastase (MMP-12) indicates an internal conformational adjustment.

Authors:  Rajagopalan Bhaskaran; Mark O Palmier; Nusayba A Bagegni; Xiangyang Liang; Steven R Van Doren
Journal:  J Mol Biol       Date:  2007-10-16       Impact factor: 5.469

8.  Modeling of enzyme-substrate complexes for the metalloproteases MMP-3, ADAM-9 and ADAM-10.

Authors:  Sergio Manzetti; Daniel R McCulloch; Adrian C Herington; David van der Spoel
Journal:  J Comput Aided Mol Des       Date:  2003-09       Impact factor: 3.686

9.  Thermodynamic Basis of Selectivity in the Interactions of Tissue Inhibitors of Metalloproteinases N-domains with Matrix Metalloproteinases-1, -3, and -14.

Authors:  Haiyin Zou; Ying Wu; Keith Brew
Journal:  J Biol Chem       Date:  2016-03-31       Impact factor: 5.157

10.  QM/MM linear response method distinguishes ligand affinities for closely related metalloproteins.

Authors:  Akash Khandelwal; Stefan Balaz
Journal:  Proteins       Date:  2007-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.